CTRI/2024/07/071087尚未招募4 期
A Comparitive study of Dapagliflozin Vs Pioglitazone in Patients of Non Alcoholic Fatty liver disease with Type 2 Diabetes Mellitus - NI
Babra0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 NAFLD Fibrosis Score(Stage 1 to Stage 3)
- •2 USG (Grade 2 & Grade 3 fatty liver)
- •3 HbA1C 6.5% & above
- •4 BMI 23 kg/m² & above
- •5 Type 2 diabetes mellitus patient on treatment of metformin (upto 2g/day)
排除标准
- •1 Patient with heart failure, kidney failure, malignancy
- •2 Pregnant & Lactating mothers
- •3 Habitual drinkers
- •4 Contraindication to dapagliflozin and pioglitazone
- •5 Use of steroid &/ or other immunosuppressor
- •6 H/o mental illness or inability to co operate
研究者
相似试验
已完成
不适用
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trialtype 2 diabetes mellitus, NAFLD, NASHJPRN-UMIN000030548Saitama Medical University Hospital100
招募中
3 期
Effects of Dapagliflozin and Empagliflozin in Myocardial DysfunctioHeart failureIRCT20111206008307N45Tabriz University of Medical Sciences75
招募中
3 期
Safety and efficacy of Dapagliflozin and sitagliptin in elderly uncontrolled type 2 diabetes mellitus patientsCTRI/2023/06/053833Dr Mukku Venkata Pratap Reddy
已完成
不适用
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)Type 2 Diabetes MellitusJPRN-UMIN000028014the Japan Society for Patient Reported Outcome (PRO)340
已完成
不适用
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (sub study)Type 2 Diabetes MellitusJPRN-UMIN000029640the Japan Society for Patient Reported Outcome (PRO)40